DIAREG - Landstinget Sörmland

Nätverket DIAREG
8. Referenser
1. Socialstyrelsen. Nationella riktlinjer för diabetesvården 2010 - Stöd för styrning och ledning.
Socialstyrelsen; 2010.
2. Läkemedelsverket. Läkemedelsbehandling vid typ 2 diabetes - ny rekommendation.
Information från Läkemedelsverket 2010;(1)10-49.
3. Cameron et al. Cost-effectiveness of insulin analogues for diabetes mellitus. Canadian Medical
Association journal 2009;180(4):400-7.
4. SFD Svensk Förening för Diabetologi. Behandlingsriktlinjer 2007. DiabetologNytt 2007(2-3).
5. Apoteket AB. Läkemedelsboken, 2009/2010: Apoteket AB; 2009.
6. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management
of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment
of therapy: a consensus statement from the American Diabetes Association and the European
Association for the Study of Diabetes. Diabetologia 2009;52(1):17-30.
7. International Diabetes Federation. IDF Clinical Guidelines Task Force. Global guideline for Type 2
diabetes. Brussels: International Diabetes Federation; 2005.
8. SBU. Intensiv glukossänkande behandling vid diabetes. En systematisk litteraturöversikt. Statens
beredning för medicinsk utvärdering, 2009.
9. TLV, Tandvårds- och läkemedelsförmånsverket. Genomgång av läkemedel vid diabetes, 2010.
10. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, et al. Long-acting insulin analogues
versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev
2007(2):CD005613.
11. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, et al. Short acting insulin analogues
versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev.
2006(2):CD003287.
12. http://www.cadth.ca/en/products/optimal-use/insulin-analog-therapy
13. The effect of intensive treatment of diabetes on the development and progression of long-term
complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial
Research Group. N Engl J Med 1993;329(14):977-86.
14. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and
risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study
(UKPDS) Group. Lancet 1998;352(9131):837-53.
15. 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes. Rury R. Holman, Sanjoy K. Paul, M.
Angelyn Bethel, David R. Matthews and H. Andrew W. Neil. N Eng J Med 2008;359:1577-89.
16. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and
cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348(5):383-93.
17. Gaede P et al. Effect of a multifactorial intervention on mortality in type 2 diabetes.
N Engl J Med 2008; 358:580-91.
18. National Institute for Health and Clinical Excellence. NICE short clinical guideline 87. Type 2 diabetes:
newer agents for blood glucose control in type 2 diabetes. In: Developed by the Centre for Clinical
Practice at NICE, editor. London; 2009.
Diabetesläkemedel Referenser Fastställt 2011-05-31
23